162. Pemphigoid Clinical trials / Disease details

Clinical trials : 83 / Drugs : 128 - (DrugBank : 51) / Drug target genes : 33 - Drug target pathways : 142

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-005987-67-DE (EUCTR)	22/12/2021	16/07/2021	A study to see if 24-weeks of treatment with nomacopan works and is safe in adult patients with bullous pemphigoid who are also being treated with steroid tablets	A randomized, part A partial blinded and part B double blinded, placebo-controlled 24-week clinical study to evaluate the efficacy and safety of nomacopan therapy in adult patients with bullous pemphigoid receiving adjunct oral corticosteroid therapy (ARREST-BP)	moderate to severe bullous pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: nomacopan Product Code: rVA576 INN or Proposed INN: NOMACOPAN Other descriptive name: rVA576	Akari Therapeutics Plc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	48	Phase 3	United States;Germany
2	NCT05061771 (ClinicalTrials.gov)	September 2021	15/9/2021	Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)	A Randomized, Part A Partial Blinded and Part B Double Blinded, Placebo-controlled 24-week Clinical Study to Evaluate the Efficacy and Safety of Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)	Bullous Pemphigoid	Drug: nomacopan (rVA576);Other: Placebo	AKARI Therapeutics	NULL	Not yet recruiting	18 Years	99 Years	All	148	Phase 3	NULL